ImmuCell Corporation (ICCC) |
| 7.65 0.54 (7.59%) 04-14 10:43 |
| Open: | 7.28 |
| High: | 7.7497 |
| Low: | 7.28 |
| Volume: | 40,423 |
| Market Cap: | 69(M) |
| PE Ratio: | -63.75 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 9.05 |
| Resistance 1: | 7.75 |
| Pivot price: | 6.67 |
| Support 1: | 6.67 |
| Support 2: | 6.00 |
| 52w High: | 7.749 |
| 52w Low: | 4.52 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| EPS | -0.120 |
| Book Value | 3.290 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.265 |
| Profit Margin (%) | -3.76 |
| Operating Margin (%) | -0.76 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | -3.6 |
Tue, 14 Apr 2026
ImmuCell Reshapes Board to Drive Innovation and Growth - TipRanks
Mon, 13 Apr 2026
ImmuCell (ICCC) adds industry veterans to a smaller, more independent board - Stock Titan
Mon, 13 Apr 2026
ImmuCell appoints two directors, expands to 7-member board - Investing.com
Mon, 13 Apr 2026
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors - The Manila Times
Mon, 13 Apr 2026
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors - The Norfolk Daily News
Mon, 13 Apr 2026
Press Release: ImmuCell Bolsters Its Innovation Strategy With Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors - Moomoo
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |